Q3 2025 ARS Pharmaceuticals Inc Earnings Call Transcript
Key Points
- U.S. net product revenue for neffy grew significantly, reaching $31.3 million in Q3, a 2.5-fold increase from the prior quarter, exceeding expectations.
- The Neffy Experience program showed that about 9 out of 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy.
- The Get neffy on Us program aims to simplify access to neffy, offering virtual prescriber interactions at no cost to patients if covered by insurance.
- neffy received approval in Japan with launches anticipated in Canada and China, indicating strong global expansion potential.
- The company secured a $250 million term loan facility, strengthening its balance sheet without dilution and supporting commercial growth initiatives.
- IQVIA's script data does not accurately reflect neffy's true performance or market share due to exclusion of certain sales channels.
- Back-to-school seasonality caused a temporary pause in market share growth due to high patient volumes and limited appointment times.
- Q4 sales are anticipated to decrease from Q3 due to typical epinephrine market seasonality and holiday impacts.
- Approximately 50% of covered lives still require prior authorization, posing a barrier to unrestricted access.
- SG&A expenses were high at $74.8 million, reflecting significant investment in DTC campaigns and sales efforts, impacting profitability.
Good morning, and welcome to ARS Pharmaceuticals conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I'll now turn the call over to Justin Chakma, Chief Business Officer. Please go ahead.
Good morning, and thank you for joining our third-quarter 2025 earnings conference Call. With me on the call are Richard Lowenthal, our Co-Founder, President and CEO; Eric Karas, our Chief Commercial Officer; and Kathy Scott, our CFO.
This morning, we issued a press release detailing our financial results and commercial highlights. That press release and the slide presentation, which we'll refer to today during today's call, are available in the Investors and Media section of our website at ars-pharma.com. Before we begin, please note that today's remarks and slide presentation may contain forward-looking statements. Actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
